- Home
- TSI vs CMPX Comparison
TSI vs CMPX Comparison
Compare TSI & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSI
- CMPX
- Stock Information
- Founded
- TSI 1987
- CMPX 2014
- Country
- TSI United States
- CMPX United States
- Employees
- TSI N/A
- CMPX 35
- Industry
- TSI Investment Managers
- CMPX Biotechnology: Pharmaceutical Preparations
- Sector
- TSI Finance
- CMPX Health Care
- Exchange
- TSI Nasdaq
- CMPX Nasdaq
- Market Cap
- TSI 234.6M
- CMPX 291.8M
- IPO Year
- TSI N/A
- CMPX N/A
- Fundamental
- Price
- TSI $4.93
- CMPX $2.10
- Analyst Decision
- TSI
- CMPX Strong Buy
- Analyst Count
- TSI 0
- CMPX 8
- Target Price
- TSI N/A
- CMPX $13.13
- AVG Volume (30 Days)
- TSI 106.8K
- CMPX 804.2K
- Earning Date
- TSI 01-01-0001
- CMPX 05-08-2025
- Dividend Yield
- TSI 7.46%
- CMPX N/A
- EPS Growth
- TSI N/A
- CMPX N/A
- EPS
- TSI N/A
- CMPX N/A
- Revenue
- TSI N/A
- CMPX $850,000.00
- Revenue This Year
- TSI N/A
- CMPX N/A
- Revenue Next Year
- TSI N/A
- CMPX N/A
- P/E Ratio
- TSI N/A
- CMPX N/A
- Revenue Growth
- TSI N/A
- CMPX N/A
- 52 Week Low
- TSI $4.48
- CMPX $0.77
- 52 Week High
- TSI $4.87
- CMPX $4.08
- Technical
- Relative Strength Index (RSI)
- TSI 56.87
- CMPX 56.95
- Support Level
- TSI $4.89
- CMPX $2.02
- Resistance Level
- TSI $4.95
- CMPX $2.23
- Average True Range (ATR)
- TSI 0.04
- CMPX 0.12
- MACD
- TSI 0.00
- CMPX 0.02
- Stochastic Oscillator
- TSI 65.00
- CMPX 66.67
About TSI TCW Strategic Income Fund Inc.
Tcw Strategic Income Fund Inc operates as a closed-end management investment company. Its investment objective is to seek a total return comprised of current income and capital appreciation by investing in a wide range of securities. The company invests in a range of industries, such as airlines, banks, beverages, biotechnology, chemicals, computers, diversified financial services, entertainment and others.
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.